{"transactions":[{"id":2710686,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":592592,"price":1.35,"value":799999.2,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.(\"Late Stage Fund\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\"), the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Each of Management 4, Pontifax IV, Late Stage Fund and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":616592,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}},{"id":2710685,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":1422222,"price":1.35,"value":1919999.7,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1989551,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}},{"id":2710684,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":2630487,"price":1.35,"value":3551157.45,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":3679797,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}},{"id":2710683,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":1280624,"price":1.35,"value":1728842.4,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1791470,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}},{"id":3137703,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":2,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":5,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148998,"kind":"organization","name":"Pontifax Management III G.P. (2011) Ltd.","position":6,"cik":"0001726335","reported_name":"Pontifax Management III G.P. (2011) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148999,"kind":"organization","name":"Pontifax Management Fund III L.P.","position":7,"cik":"0001726340","reported_name":"Pontifax Management Fund III L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149000,"kind":"organization","name":"Pontifax (Cayman) III, L.P.","position":8,"cik":"0001726028","reported_name":"Pontifax (Cayman) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149001,"kind":"organization","name":"Pontifax (Israel) III, L.P.","position":9,"cik":"0001726038","reported_name":"Pontifax (Israel) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-22T20:10:59.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned by Ran Nussbaum, a director of Pontifax. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":3.39,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-20-001306","document":"form4-05222020_040544.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920001306/form4-05222020_040544.xml","form_type":"4"}},{"id":3137702,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":2,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":5,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148998,"kind":"organization","name":"Pontifax Management III G.P. (2011) Ltd.","position":6,"cik":"0001726335","reported_name":"Pontifax Management III G.P. (2011) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148999,"kind":"organization","name":"Pontifax Management Fund III L.P.","position":7,"cik":"0001726340","reported_name":"Pontifax Management Fund III L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149000,"kind":"organization","name":"Pontifax (Cayman) III, L.P.","position":8,"cik":"0001726028","reported_name":"Pontifax (Cayman) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149001,"kind":"organization","name":"Pontifax (Israel) III, L.P.","position":9,"cik":"0001726038","reported_name":"Pontifax (Israel) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-22T20:10:59.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Tomer Kariv, a director of Pontifax Management 4 G.P. (2015) Ltd. and Pontifax Management III G.P. (2011) Ltd. (collectively, \"Pontifax\").\n\nPontifax Management 4.G.P. (2015) Ltd., is the general partner of Pontifax Management 4 G.P. L.P., which is the general partner of each of Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P. and Pontifax (Israel) IV L.P.\n\nPontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P., which is the general partner of each of Pontifax (Cayman) III L.P. and Pontifax (Israel) III L.P.\n\nMr. Kariv will assign the economic interests of the reported securities to Pontifax; and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":3.39,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-20-001306","document":"form4-05222020_040544.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920001306/form4-05222020_040544.xml","form_type":"4"}},{"id":3478187,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:44:05.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":24000,"price":9,"value":216000.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.(\"Late Stage Fund\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\"), the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Each of Management 4, Pontifax IV, Late Stage Fund and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":24000,"source":{"system":"sec-edgar","filing":"0001144204-19-032482","document":"tv524335_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032482/tv524335_form4.xml","form_type":"4"}},{"id":3478186,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:44:05.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":46933,"price":9,"value":422397.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":567329,"source":{"system":"sec-edgar","filing":"0001144204-19-032482","document":"tv524335_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032482/tv524335_form4.xml","form_type":"4"}},{"id":3478185,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:44:05.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":86806,"price":9,"value":781254.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1049310,"source":{"system":"sec-edgar","filing":"0001144204-19-032482","document":"tv524335_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032482/tv524335_form4.xml","form_type":"4"}},{"id":3478184,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:44:05.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":42261,"price":9,"value":380349.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":510846,"source":{"system":"sec-edgar","filing":"0001144204-19-032482","document":"tv524335_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032482/tv524335_form4.xml","form_type":"4"}},{"id":3509085,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":2,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":5,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148998,"kind":"organization","name":"Pontifax Management III G.P. (2011) Ltd.","position":6,"cik":"0001726335","reported_name":"Pontifax Management III G.P. (2011) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148999,"kind":"organization","name":"Pontifax Management Fund III L.P.","position":7,"cik":"0001726340","reported_name":"Pontifax Management Fund III L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149000,"kind":"organization","name":"Pontifax (Cayman) III, L.P.","position":8,"cik":"0001726028","reported_name":"Pontifax (Cayman) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149001,"kind":"organization","name":"Pontifax (Israel) III, L.P.","position":9,"cik":"0001726038","reported_name":"Pontifax (Israel) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-29T21:15:22.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half (1/2) of the shares underlying the option shall vest on May 29, 2020 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned by Ran Nussbaum, a director of Pontifax. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":9.02,"expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-19-000624","document":"form4-05292019_020508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588919000624/form4-05292019_020508.xml","form_type":"4"}},{"id":3509084,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":2,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":5,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148998,"kind":"organization","name":"Pontifax Management III G.P. (2011) Ltd.","position":6,"cik":"0001726335","reported_name":"Pontifax Management III G.P. (2011) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148999,"kind":"organization","name":"Pontifax Management Fund III L.P.","position":7,"cik":"0001726340","reported_name":"Pontifax Management Fund III L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149000,"kind":"organization","name":"Pontifax (Cayman) III, L.P.","position":8,"cik":"0001726028","reported_name":"Pontifax (Cayman) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149001,"kind":"organization","name":"Pontifax (Israel) III, L.P.","position":9,"cik":"0001726038","reported_name":"Pontifax (Israel) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-29T21:15:22.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half (1/2) of the shares underlying the option shall vest on May 29, 2020 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Tomer Kariv, a director of Pontifax Management 4 G.P. (2015) Ltd. and Pontifax Management III G.P. (2011) Ltd. (collectively, \"Pontifax\").\n\nPontifax Management 4.G.P. (2015) Ltd., is the general partner of Pontifax Management 4 G.P. L.P., which is the general partner of each of Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P. and Pontifax (Israel) IV L.P.\n\nPontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P., which is the general partner of each of Pontifax (Cayman) III L.P. and Pontifax (Israel) III L.P.\n\nMr. Kariv will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":9.02,"expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-19-000624","document":"form4-05292019_020508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588919000624/form4-05292019_020508.xml","form_type":"4"}},{"id":3889181,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":2,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":3,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-19T22:19:46.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Ran Nussbaum, a general partner of Pontifax 4.  Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax 4 and it may be deemed the indirect beneficial owner of the security. Pontifax 4 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":40000,"derivative":{"exercise_price":23.27,"expiration_date":"2028-06-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-18-038660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118038660/doc4.xml","form_type":"4"}},{"id":3889180,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":2,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":3,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-19T22:19:46.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Tomer Kariv, a general partner of Pontifax Management 4 G.P. (2015) Ltd. (\"Pontifax 4\").  Mr. Kariv will assign the economic interests of the reported securities to Pontifax 4 and it may be deemed the indirect beneficial owner of the security. Pontifax 4 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":40000,"derivative":{"exercise_price":23.27,"expiration_date":"2028-06-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-18-038660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118038660/doc4.xml","form_type":"4"}},{"id":3952308,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T20:37:26.000Z","date":"2018-04-30","kind":"purchase","acquired":true,"shares":93333,"price":9.75,"value":909996.75,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":520396,"source":{"system":"sec-edgar","filing":"0001209191-18-027114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118027114/doc4.xml","form_type":"4"}},{"id":3952307,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T20:37:26.000Z","date":"2018-04-30","kind":"purchase","acquired":true,"shares":172626,"price":9.75,"value":1683103.5,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":962504,"source":{"system":"sec-edgar","filing":"0001209191-18-027114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118027114/doc4.xml","form_type":"4"}},{"id":3952306,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T20:37:26.000Z","date":"2018-04-30","kind":"purchase","acquired":true,"shares":84041,"price":9.75,"value":819399.75,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":468585,"source":{"system":"sec-edgar","filing":"0001209191-18-027114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118027114/doc4.xml","form_type":"4"}},{"id":3984105,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-22","kind":"purchase","acquired":true,"shares":1600,"price":8,"value":12800.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":427063,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}},{"id":3984104,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-22","kind":"purchase","acquired":true,"shares":2959,"price":8,"value":23672.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":789878,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}},{"id":3984103,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-22","kind":"purchase","acquired":true,"shares":1441,"price":8,"value":11528.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":384544,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}},{"id":3984102,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-21","kind":"purchase","acquired":true,"shares":1760,"price":7.55,"value":13288.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":425463,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}},{"id":3984101,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-21","kind":"purchase","acquired":true,"shares":3255,"price":7.55,"value":24575.25,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":786919,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}},{"id":3984100,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-21","kind":"purchase","acquired":true,"shares":1585,"price":7.55,"value":11966.75,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":383103,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}}]}